Cannabidiol review
Pro Research Analysisby 
Searched over 200M research papers for "cannabidiol review"
Cannabidiol (CBD) Review: Pharmacokinetics, Dosing, Safety, and Therapeutic Potential
Pharmacokinetics of Cannabidiol in Humans
Bioavailability and Half-Life
Cannabidiol (CBD) exhibits varying pharmacokinetic properties depending on the route of administration. The bioavailability of CBD is notably higher when smoked (31%) compared to other routes such as oral or oromucosal delivery, where comprehensive data is lacking . The half-life of CBD also varies significantly: it ranges from 1.4 to 10.9 hours after oromucosal spray, 2-5 days following chronic oral administration, 24 hours after intravenous administration, and 31 hours after smoking . These variations highlight the need for more robust data to understand the pharmacokinetics of CBD fully.
Dose-Dependent Absorption
The area-under-the-curve (AUC) and maximum concentration (Cmax) of CBD increase in a dose-dependent manner, with quicker absorption observed through smoking or inhalation compared to oral or oromucosal routes . Additionally, Cmax is higher when CBD is taken with food or in lipid formulations, with the time to reach maximum concentration (Tmax) ranging between 0 and 4 hours .
Dosing in Clinical Populations
Effective Doses Across Conditions
CBD has been studied across various medical conditions with doses ranging from less than 1 mg/kg/day to 50 mg/kg/day. Significant improvements in primary outcomes, such as reductions in psychotic symptoms, anxiety, and seizures, have been reported in 23 out of 35 studies . Notably, epilepsy was the most frequently studied condition, with all 11 studies showing positive effects on seizure reduction at an average dose of 15 mg/kg/day . However, low doses (average 2.4 mg/kg/day) used in studies on diabetes, Crohn's disease, ocular hypertension, fatty liver disease, and chronic pain did not show significant positive activity .
Safety and Adverse Effects
General Safety Profile
CBD is generally well-tolerated, but it is associated with some adverse effects. A meta-analysis of randomized clinical trials revealed an increased likelihood of withdrawal due to adverse events, serious adverse events, and specific issues such as abnormal liver function tests, pneumonia, decreased appetite, diarrhea, somnolence, and sedation . These adverse effects were particularly noted in studies involving childhood epilepsy, where CBD may interact with other medications like clobazam and sodium valproate . Outside of childhood epilepsy, the primary adverse effect associated with CBD was diarrhea .
Therapeutic Potential in Anxiety and Psychiatric Disorders
Anxiety Disorders
CBD has shown promise as an alternative therapy for anxiety and anxiety-related disorders. Studies have demonstrated improved clinical outcomes in generalized anxiety disorder, social anxiety disorder, and the anxiety component of posttraumatic stress syndrome, with doses ranging from 6 mg to 400 mg per dose . CBD was generally well-tolerated, with minimal adverse effects such as fatigue and sedation .
Psychiatric Disorders
The evidence for CBD's efficacy in treating psychiatric disorders like schizophrenia, psychotic disorders, and substance-use disorders is still emerging. While some studies suggest potential benefits, the overall evidence remains limited and inconclusive . The most frequently reported adverse effects in these studies were sedation and dizziness .
Biological Effects on Healthy Cells
Cell Viability and Inflammation
CBD has been shown to inhibit cell viability in a dose-dependent manner above 2 µM and significantly inhibit cell migration and proliferation at higher doses . It also stimulates apoptosis at high doses (from 10 µM) and exhibits anti-inflammatory effects by reducing pro-inflammatory cytokine gene expression and secretion . These findings underscore the importance of defining specific concentration thresholds to ensure safe therapeutic use.
Conclusion
Cannabidiol (CBD) holds significant potential as a therapeutic agent across various medical conditions, particularly in epilepsy and anxiety disorders. However, its pharmacokinetics, optimal dosing strategies, and safety profile require further investigation. While generally well-tolerated, CBD can cause adverse effects, especially when interacting with other medications. More robust clinical trials and pharmacokinetic studies are essential to fully understand and harness the therapeutic benefits of CBD.
Sources and full results
Most relevant research papers on this topic